{
  "id": "mhgap#risk_safety_e2055418",
  "content": "lamotrigine or levetiracetam should be offered as first-line monotherapy for\nboth generalized onset seizures and focal onset seizures.\nWomen with epilepsy should have seizures controlled as well as possible with\nthe minimum dose of ASMs taken in monotherapy, wherever possible.\nValproic acid (sodium valproate) is not recommended in women and girls of\nchildbearing potential because of potential harm to the fetus.\nStrength of recommendation: Strong\nCertainty of evidence: Very low\n4.2 Standard breastfeeding recommendations remain appropriate for\nwomen with epilepsy taking the ASMs included in this review (phenobarbital,\nphenytoin, valproic acid [sodium valproate], carbamazepine, lamotrigine,\nlevetiracetam, topiramate, lacosamide).\nStrength of recommendation: Strong\nCertainty of evidence: Very low\n82\n3. Recommendations\nJustification Research gaps\ny Evidence was extracted from one systematic review y Most of the research is from HICs. Further research is\nand NMA: Veroniki et al., 2017 (96 studies; 92 cohort needed in LMICs.\nstudies, 3 case–control studies and 1 RCT) (184). y There were no data on the side-effects related to\ny Most ASMs are associated with higher risks of major ASM exposure exclusively through breast-milk. It\ncongenital malformations in offspring of women is, though, noted that the amount of ASM in breast-",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "risk_safety",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety lamotrigine or levetiracetam should be offered as first-line monotherapy for\nboth generalized onset seizures and focal onset seizures.\nWomen with epilepsy should have seizures controlled as well as possible with\nthe minimum dose of ASMs taken in monotherapy, wherever possible.\nValproic acid (sodium valproate) is not recommended in women and girls of\nchildbearing potential because of potential harm to the fetus.\nStrength of recommendation: Strong\nCertainty of evidence: Very low\n4.2 Standard breastfeeding recommendations remain appropriate for\nwomen with epilepsy taking the ASMs included in this review (phenobarbital,\nphenytoin, valproic acid [sodium valproate], carbamazepine, lamotrigine,\nlevetiracetam, topiramate, lacosamide).\nStrength of recommendation: Strong\nCertainty of evidence: Very low\n82\n3. Recommendations\nJustification Research gaps\ny Evidence was extracted from one systematic review y Most of the research is from HICs. Further research is\nand NMA: Veroniki et al., 2017 (96 studies; 92 cohort needed in LMICs.\nstudies, 3 case–control studies and 1 RCT) (184). y There were no data on the side-effects related to\ny Most ASMs are associated with higher risks of major ASM exposure exclusively through breast-milk. It\ncongenital malformations in offspring of women is, though, noted that the amount of ASM in breast- Lamotrigine or levetiracetam should be offered as first-line monotherapy for\nboth generalized onset seizures and focal onset seizures. women with epilepsy should have seizures controlled as well as possible with\nthe mini..."
}